Yazdanparast Somayeh, Huang Zoufang, Keramat Shayan, Izadirad Mehrdad, Li Yi-Dong, Bo Letao, Gharehbaghian Ahmad, Chen Zhe-Sheng
Department of Hematology and Blood Bank, School of Allied Medical Science, Shahid Beheshti University of Medical Science, Tehran, Iran.
Ganzhou Key Laboratory of Hematology, Department of Hematology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, China.
Front Oncol. 2022 Jun 2;12:904637. doi: 10.3389/fonc.2022.904637. eCollection 2022.
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous neoplasm and is characterized as the most common subtype of non-Hodgkin lymphoma (NHL). Despite 60-70% of all patients being cured with R-CHOP therapeutic regimen (Cyclophosphamide, doxorubicin, vincristine, and prednisone, combined with rituximab), remaining patients display aggressive disease. Therefore, there is an urgent need to develop novel diagnostic, prognostic, and predictive biomarkers. Recently, exosomal miRNAs have been approved as novel biomarkers in DLBCL due to their potential involvement in lymphomagenesis.
We conducted an investigation on the potential role of exosomal miRNAs as diagnostic, prognostic, and predictive biomarkers in DLBCL in the PubMed, Scopus, and Web of Science search engines. We searched by using a combination of keywords, such as diffuse large B-cell lymphoma, DLBCL, miRNA, microRNA, miR, exosome, exosomes, exosomal, extracellular vesicles, EVs, and secretome. Then, search results were narrowed based on specific inclusion and exclusion criteria.
Twelve articles were eligible for our systematic reviews. Among them, nine discussed diagnostic biomarkers, three considered prognostic significance, four evaluated therapeutic efficacy, two studies were conducted , and three assessed molecular pathways associated with these exosomal miRNAs in DLBCL.
According to our systematic review, exosomal miRNAs are not only useful for diagnosis and prognosis in DLBCL but are also promising therapeutic tools and predictors of response to therapy. Although promising results so far, more research is required to develop innovative biomarkers.
弥漫性大B细胞淋巴瘤（DLBCL）是一种异质性肿瘤，是最常见的非霍奇金淋巴瘤（NHL）亚型。尽管所有患者中有60 - 70%可通过R-CHOP治疗方案（环磷酰胺、阿霉素、长春新碱和泼尼松联合利妥昔单抗）治愈，但其余患者仍表现出侵袭性疾病。因此，迫切需要开发新的诊断、预后和预测生物标志物。最近，外泌体miRNA因其可能参与淋巴瘤发生而被批准作为DLBCL的新型生物标志物。
我们在PubMed、Scopus和Web of Science搜索引擎中对DLBCL中外泌体miRNA作为诊断、预后和预测生物标志物的潜在作用进行了调查。我们使用了诸如弥漫性大B细胞淋巴瘤、DLBCL、miRNA、微小RNA、miR、外泌体、外泌体、外泌体的、细胞外囊泡、EVs和分泌组等关键词组合进行搜索。然后，根据特定的纳入和排除标准缩小搜索结果范围。
12篇文章符合我们的系统评价标准。其中，9篇讨论了诊断生物标志物，3篇考虑了预后意义，4篇评估了治疗效果，进行了2项研究，3篇评估了DLBCL中与这些外泌体miRNA相关的分子途径。
根据我们的系统评价，外泌体miRNA不仅对DLBCL的诊断和预后有用，而且还是有前景的治疗工具和治疗反应预测指标。尽管目前取得了令人鼓舞的结果，但仍需要更多研究来开发创新的生物标志物。
